Thomas Aparicio
- Gastroenterology top 0.2%
- Gastrointestinal Tumor Research and Treatment 42
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies 97
- Pancreatic and Hepatic Oncology Research 32
- Cancer Treatment and Pharmacology 24
- Colorectal Cancer Surgical Treatments 21
- Geriatrics and Gerontology top 1%
-
- Gastric Cancer Management and Outcomes 84
- Cancer Research top 2%
-
- Genetic factors in colorectal cancer 38
-
- Hepatocellular Carcinoma Treatment and Prognosis 23
Thomas Aparicio
236 papers receiving 6.4k citations
Hit Papers
Peers
Comparison fields: 5 of 127
- Gastroenterology 1.1k
- Oncology 3.6k
- Geriatrics and Gerontology 360
- Pulmonary and Respiratory Medicine 2.1k
- Cancer Research 866
Countries citing papers authored by Thomas Aparicio
This map shows the geographic impact of Thomas Aparicio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Aparicio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Aparicio more than expected).
Fields of papers citing papers by Thomas Aparicio
This network shows the impact of papers produced by Thomas Aparicio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Aparicio. The network helps show where Thomas Aparicio may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Thomas Aparicio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2023 | 5 | |
| 3 | 2023 | 5 | |
| 4 | 2023 | 7 | |
| 5 | 2023 | 0 | |
| 6 | Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Studybreakdown → | 2022 | 220 |
| 7 | 2022 | 30 | |
| 8 | 2022 | 2 | |
| 9 | 2021 | 4 | |
| 10 | 2021 | 16 | |
| 11 | 2021 | 6 | |
| 12 | 2020 | 14 | |
| 13 | 2018 | 24 | |
| 14 | 2018 | 24 | |
| 15 | 2018 | 5 | |
| 16 | 2014 | 27 | |
| 17 | 2013 | 154 | |
| 18 | Effects of Intragastric Balloon on Weight Loss, Physical Activity, Plasma Leptin and Ghrelin in Obese Patients, with Long-Term Follow-Up | 2013 | 2 |
| 19 | 2008 | 33 | |
| 20 | Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. | 2004 | 29 |
About Thomas Aparicio
Thomas Aparicio is a scholar working on Gastroenterology, Oncology, Geriatrics and Gerontology, Hepatology and Pulmonary and Respiratory Medicine, having authored 254 papers that have together received 6.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (97 papers), Gastric Cancer Management and Outcomes (84 papers), Gastrointestinal Tumor Research and Treatment (42 papers), Genetic factors in colorectal cancer (38 papers), Pancreatic and Hepatic Oncology Research (32 papers), Cancer Treatment and Pharmacology (24 papers), Hepatocellular Carcinoma Treatment and Prognosis (23 papers) and Colorectal Cancer Surgical Treatments (21 papers). The work is most often cited by research in Gastroenterology (1.1k citations), Oncology (3.6k citations), Geriatrics and Gerontology (360 citations), Pulmonary and Respiratory Medicine (2.1k citations) and Cancer Research (866 citations). Thomas Aparicio has collaborated with scholars based in France, Italy and United States. Frequent co-authors include P. Rougier, Olivier Bouché, Michel Ducreux, Aziz Zaanan, Julien Taı̈eb, Emmanuel Mitry, Thierry Lecomte, Laurent Bedenne, Iradj Sobhani and Pierre Laurent‐Puig. Their work appears in journals such as Journal of Clinical Oncology, Digestive and Liver Disease, Annals of Oncology, European Journal of Cancer and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.